The demand for donated blood is rising because of advancements in healthcare systems and the availability of and the need for sophisticated surgical procedures, such as cardiovascular & transplant surgery, trauma care, and therapy for cancer and blood diseases. Emerging economies such as China, Japan, and India are providing lucrative opportunities for the players operating in the market.
The global Blood screening market is projected to reach USD 3.8 billion by 2026 from USD 2.5 billion in 2021, at a CAGR of 8.4%.
Download PDF Brochure:- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=267747042
Scope of the Report
This report categorizes the blood screening market into the following segments and subsegments:
By Product & Service
• Reagents & Kits
o NAT Reagents & Kits
 Enzymes & Polymerases
 Standards & Controls
 Probes & Primers
 Buffers, Nucleotides, and Solutions
 Labeling & Detection Reagents
o ELISA Reagents & Kits
 Immunosorbents
 Controls
 Conjugates
 Substrates
 Sample Diluents & Wash Solutions
o Other Reagents & Kits
• Instruments
o Rental Purchase
o Outright Purchase
• Software & Services
By Technology
• Nucleic Acid Test
o Transcription-mediated Amplification
o Real-time PCR
• ELISA
o Chemiluminescent Immunoassays
o Fluorescent Immunoassays
o Colorimetric Immunoassays
• Rapid Tests
• Western Blot Assays
• Next-generation Sequencing
By End User
• Blood Banks
• Hospitals
By Region
• North America
o US
o Canada
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe
• Asia Pacific
o China
o Japan
o India
o Australia
o Rest of Asia Pacific
• Latin America
o Australia
o Rest of Latin America
• Middle East & Africa
Market Segmentation: -
The blood screening market is segmented into reagents & kits, instruments, and software & services. The reagents & kits accounted for the largest share of the market in 2020, mainly due to repeated use of reagents & kits in blood screening procedures due to the rising blood transfusion procedures, and the high consumption.
The blood screening market is segmented into nucleic acid test (NAT), enzyme-linked immunosorbent assay (ELISA), rapid tests, western blot assays, and next-generation sequencing (NGS). In 2020, the nucleic acid test (NAT) segment accounted for the largest share of the market. Factors such as the increasing adoption of NAT technology due to its higher sensitivity over other blood screening technologies and increasing number of blood donations.
Based on end users, the blood screening market is segmented into blood banks and hospitals. In 2020, the blood banks segment accounted for the largest share of the market. The growing number of organ transplantation surgeries is driving the growth of this segment, and the increasing demand for donated blood.
Regional Analysis:
The global market is segmented into five major regions—north America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2020, North America accounted for the largest share of the market. The North American market growth can be attributed to the increasing healthcare spending, increasing prevalence of chronic disorders, and the highly developed healthcare system in the US and Canada.
Request Sample Pages:- https://www.marketsandmarkets.com/requestsampleNew.asp?id=267747042
Top key Players:-
The major players operating in this blood screening market are Grifols (Spain), F. Hoffmann-La Roche Ltd. (Switzerland), Abbott Laboratories, Inc. (US), bioMérieux (France), Bio-Rad Laboratories, Inc. (US), Becton, Dickinson and Company (US), Beckman Coulter, Inc. (Danaher) (US), DiaSorin (Italy), Siemens Healthineers (Germany), Thermo Fisher Scientific, Inc. (US), Ortho Clinical Diagnostics Inc. (US), GE Healthcare (US), Merck KGaA (Germany), PerkinElmer (US), Bio-Techne Corporation (US), GFE (Germany), Trinity Biotech (Ireland), Mindray (China), Maccura Biotechnology Co., Ltd. (China), Immucor, Inc. (US), Cellabs (Australia), Abnova Corporation (Taiwan), Enzo Biochem, Inc. (US), and Cepheid (US).